Trinity Bio ADR (TRIB) Stock Price, Quote & News

Company Profile

Trinity Biotech plc acquires, together with its subsidiaries, develops, acquires, manufactures, and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market in the Americas, Asia, Africa, and Europe. The company offers clinical laboratory products, including diagnostic tests and instrumentation, which detects infectious diseases; sexually transmitted diseases consisting of syphilis and herpes; SARS-CoV-2; and epstein barr, measles,...

Industry: Medical Devices

Sector: Healthcare

Phone: 353 1 276 9800

Fax: 353 1 276 9888

Website: www.trinitybiotech.com

Address:

IDA Business Park, Bray, Ireland

deepthinker Mar. 20 at 9:46 PM

$TRIB I think Gillard has tried, but things have moved too slowly on the development front. Perhaps they’ll surprise us with a CGM which draws more interest soon, but the market’s sort of lost interest.

1 · Reply

deepthinker Mar. 20 at 9:39 PM

$TRIB Given the stock price struggles, it’s becoming more apparent that they won’t have the funds going forward to develop their four programs and fund the debt, even though they do spin off some cash from existing businesses. Therefore, it seems likely that they company will be sold in whole or in part sometime soon. It’s pretty clear that the CGM hasn’t found a partnership which doesn’t give away too much for too little.

0 · Reply

OfficialStocktwitsUser Mar. 19 at 11:45 AM

$TRIB RSI: 46.94, MACD: -0.0129 Vol: 0.03, MA20: 0.72, MA50: 0.76 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.

0 · Reply

Think_Bigly Mar. 19 at 1:07 AM

$TRIB Projected growth: $15.3B > $31.4B by 2031. Big targets. Big eyes. -CGM+ is uniquely positioned at the confluence of advanced glucose monitoring technology, AI-native healthcare analytics, and increasing demand for AI wearables. Market dynamics indicate strong growth in these already sizeable markets and recent forecasts predict strong growth in the coming years: Global CGM Market: Projected to grow from $15.3B in 2026 to $31.4B by 2031 (CAGR: 15.4%)1 AI in Healthcare: Forecast to reach approximately $250B by 2031, growing at a 35.7% CAGR2 Wearable AI: Expected to reach $360B by 2034, growing at a 24.7% CAGR3

0 · Reply

deepthinker Mar. 18 at 8:29 PM

$TRIB This looks like another pump PR, but it’s not. I have more info on this, but will keep it under wraps for now.

2 · Reply

ajmore Mar. 18 at 12:45 PM

$TRIB and more positive news! keep adding products.

0 · Reply

JackLalayne1 Mar. 17 at 11:26 AM

$TRIB Finally broke through resistance at .80… Irish Prime Minister meeting in the White House today. Could be an interesting day.

0 · Reply

WAYWARD_SUN Mar. 13 at 8:49 PM

$TRIB 👀

0 · Reply

ajmore Mar. 13 at 5:27 PM

$TRIB Time to add! added

0 · Reply

Clydagh Mar. 13 at 9:15 AM

$TRIB I have put my money where my mouth is. I have backed up the truck and loaded her up. We are very close now ...

1 · Reply

Trinity Biotech Announces Collaboration with University at Buffalo to Commercialize Novel Biomarkers for Sjögren's Syndrome

Mar 12, 2026, 9:00 AM EDT - 9 days ago

Trinity Biotech Begins Rollout of Innovative Glucose Monitoring System In Key Market Following Regulatory Approval of Next-Generation Premier Hb9210 HbA1c Column System

Mar 11, 2026, 9:00 AM EDT - 10 days ago

Trinity Biotech Senior Executives to Attend ATTD 2026 to Advance Collaborations Following Strong Progress in CGM Program

Mar 10, 2026, 7:55 AM EDT - 11 days ago

Trinity Biotech Announces Further Major Technical Breakthroughs in Advancing Next Generation CGM+ Platform

Mar 10, 2026, 7:45 AM EDT - 11 days ago

Trinity Biotech Provides Business and Trading Update

Feb 25, 2026, 9:00 AM EST - 24 days ago

Trinity Biotech Secures $25 Million Financing Commitment to Support Growth Initiatives

Feb 20, 2026, 5:00 PM EST - 4 weeks ago

Trinity Biotech Receives Non-Compliance Notice Regarding Nasdaq Global Select Requirement for Minimum Market Value of Publicly Held Shares

Feb 13, 2026, 5:00 PM EST - 5 weeks ago

Trinity Biotech Receives Non-Compliance Notice Regarding Nasdaq Global Select Requirement for Nasdaq Minimum Bid Price Requirement

Feb 10, 2026, 1:28 PM EST - 5 weeks ago

Trinity Biotech Secures Regulatory Approval for Commencement of Upstream Manufacturing Activities of Uni-Gold™ HIV Rapid Test Under Its Offshored and Outsourced Model, Supporting Financial Performance Transformation

Feb 10, 2026, 8:00 AM EST - 5 weeks ago

Trinity Biotech Glucose Monitoring Innovation Achieves Unique Global Recognition: Diabetes Care Premier Hb9210™ HbA1c Analyser Becomes the Only System Awarded Prestigious IFCC Gold Classification for 2026

Dec 23, 2025, 8:50 AM EST - 3 months ago

Trinity Biotech Announces Agreements to Strengthen Capital Structure and Support Growth Initiatives

Dec 23, 2025, 7:32 AM EST - 3 months ago

Trinity Biotech Awarded a Major Order for 9 Million TrinScreen HIV Tests

Dec 15, 2025, 9:15 AM EST - 3 months ago

Trinity Biotech Expands Global Rollout of High-Capacity Column System for FDA-Cleared HbA1c Testing Solution After Securing Regulatory Clearances

Nov 18, 2025, 9:00 AM EST - 4 months ago

Trinity Biotech Secures Major Regulatory Approval for Offshored and Outsourced Manufacturing of Its Market Leading Uni-Gold Rapid HIV Test, Further Accelerating Financial Performance Transformation

Nov 14, 2025, 9:00 AM EST - 4 months ago

Trinity Biotech Announces Collaboration to Advance Epigenetic Analysis for EpiCapture Prostate Cancer Test

Oct 27, 2025, 9:00 AM EDT - 5 months ago

Trinity Biotech Welcomes Perceptive Advisor's Indication of Potential Debt-to-Equity Conversion - Strengthening Balance Sheet and Supporting Growth

Sep 2, 2025, 9:30 AM EDT - 7 months ago

Trinity Biotech Regains Compliance with Nasdaq Listing Requirements

Aug 21, 2025, 9:00 AM EDT - 7 months ago

Trinity Biotech Appoints Paul Tivnan as Non-Executive Director

Aug 20, 2025, 9:00 AM EDT - 7 months ago

Regulatory Approval Granted for Commencement of Trinity Biotech's Offshored and Outsourced Manufacturing of its Flagship Rapid HIV Test, Facilitating Strategic and Financial Performance Transformation

Aug 14, 2025, 9:00 AM EDT - 7 months ago

Trinity Biotech Receives Regulatory Approval to Begin FDA-Cleared PreClara™ Preeclampsia Testing Service

Aug 12, 2025, 8:45 AM EDT - 7 months ago

Trinity Biotech Achieves Breakthrough Clinical Trial Results for Redesigned CGM Sensor

Aug 7, 2025, 8:00 AM EDT - 8 months ago

Trinity Biotech Announces Launch of FDA-cleared Preeclampsia Testing Service

Jul 24, 2025, 8:20 AM EDT - 8 months ago

Trinity Biotech Unveils CGM+: An AI-Native Platform Targeting the $260 Billion AI Wearable Market

Jul 1, 2025, 9:00 AM EDT - 9 months ago

Trinity Biotech Reaches Profitability Inflection Point, Marking Major Milestone in Strategic Turnaround

Jun 24, 2025, 8:00 AM EDT - 9 months ago

Trinity Biotech Secures Key Regulatory Approval for Offshored and Outsourced Manufacturing of Its Flagship Rapid HIV Test, Accelerating Strategic & Financial Performance Transformation

May 15, 2025, 4:00 PM EDT - 11 months ago

Trinity Biotech Publishes Fourth Quarter and Fiscal Year 2024 Financial Results & Provides a Business Update

Mar 14, 2025, 4:30 PM EDT - 1 year ago

Trinity Biotech Receives Non-Compliance Notice Regarding Nasdaq Global Select Requirement for Minimum Market Value of Publicly Held Shares and Nasdaq Minimum Bid Price Requirement

Mar 13, 2025, 7:30 AM EDT - 1 year ago

Trinity Biotech Further Strengthens Focus on Continuous Glucose Monitoring – Appoints Barclays to Advise on Ongoing Strategic Realignment Process

Feb 28, 2025, 8:30 AM EST - 1 year ago

Trinity Biotech Announces Additional Funding To Support Transformation Plan & Continued Development of the Company's Continuous Glucose Monitoring Technology

Feb 6, 2025, 7:30 AM EST - 1 year ago

Trinity Biotech Reports Landmark First-Day Accuracy Gains in CGM Pre-Pivotal Trial

Jan 28, 2025, 7:20 AM EST - 1 year ago

Trinity Biotech Announces Breakthrough Results From Pre-Pivotal Trial of Disruptive Continuous Glucose Monitoring (CGM) Technology

Dec 24, 2024, 8:33 AM EST - 1 year ago

Trinity Biotech Announces Amended Credit Agreement with Perceptive to Enhance Liquidity and Drive Transformation Plan

Dec 18, 2024, 11:00 AM EST - 1 year ago

Trinity Biotech Receives Early Approval from the World Health Organization to Begin Offshore Manufacturing of TrinScreen HIV & Uni-Gold HIV

Nov 15, 2024, 9:00 AM EST - 1 year ago

Trinity Biotech Announces Q3 2024 Financial Results

Nov 14, 2024, 8:07 AM EST - 1 year ago

Trinity Biotech to Announce Q3 2024 Financial Results

Oct 25, 2024, 8:45 AM EDT - 1 year ago

Trinity Biotech Announces Strategic Investment in Novus Diagnostics to Advance Rapid Sepsis Testing Platform

Oct 25, 2024, 8:45 AM EDT - 1 year ago

Trinity Biotech Enters Oncology Space with Acquisition of Prostate Cancer Focused EpiCapture

Oct 7, 2024, 8:15 AM EDT - 1 year ago

Trinity Biotech Announces Positive Pre-Pivotal Trial Results for Its Next-Generation Continuous Glucose Monitor Technology

Sep 24, 2024, 4:05 PM EDT - 1 year ago

Trinity Biotech Announces Acquisition of Metabolomics Diagnostics to Grow Presence in Maternal Health Market

Sep 18, 2024, 4:05 PM EDT - 1 year ago

Trinity Biotech to Initiate CGM Market Study in India in Furtherance of Intended Collaboration with Bayer

Sep 9, 2024, 4:05 PM EDT - 1 year ago

Trinity Biotech Provides an Update on the Continued Development of Its Continuous Glucose Monitor Technology

Sep 3, 2024, 9:55 AM EDT - 1 year ago

Trinity Biotech Appoints Global Life Sciences Leader as Chief Commercial Officer

Aug 26, 2024, 4:05 PM EDT - 1 year ago

Trinity Biotech Announces Increased Orders for TrinScreen HIV and Raises Guidance For 2024 Sales

Aug 20, 2024, 5:00 PM EDT - 1 year ago

Trinity Biotech Appoints Diabetes Care Veteran as Biosensor Marketing Director

Aug 14, 2024, 7:30 AM EDT - 1 year ago

Trinity Biotech Announces Q2 2024 Financial Results

Aug 13, 2024, 4:05 PM EDT - 1 year ago

Trinity Biotech to Announce Q2 2024 Financial Results

Aug 6, 2024, 4:05 PM EDT - 1 year ago

Trinity Biotech Obtains an Extension to Demonstrate Compliance With Nasdaq Listing Requirements

Aug 2, 2024, 9:24 AM EDT - 1 year ago

Trinity Biotech Provides Preliminary Second Quarter 2024 Update and Enters into UK Distribution Agreement with MedScience

Jul 9, 2024, 4:05 PM EDT - 1 year ago

Trinity Biotech Announces Appointment of A New CFO

Jun 24, 2024, 7:00 AM EDT - 1 year ago

Trinity Biotech to Begin European Pre-Pivotal Trial to Optimize its CGM Sensor

deepthinker Mar. 20 at 9:46 PM

1 · Reply

deepthinker Mar. 20 at 9:39 PM

0 · Reply

OfficialStocktwitsUser Mar. 19 at 11:45 AM

0 · Reply

Think_Bigly Mar. 19 at 1:07 AM

0 · Reply

deepthinker Mar. 18 at 8:29 PM

$TRIB This looks like another pump PR, but it’s not. I have more info on this, but will keep it under wraps for now.

2 · Reply

ajmore Mar. 18 at 12:45 PM

$TRIB and more positive news! keep adding products.

0 · Reply

JackLalayne1 Mar. 17 at 11:26 AM

$TRIB Finally broke through resistance at .80… Irish Prime Minister meeting in the White House today. Could be an interesting day.

0 · Reply

WAYWARD_SUN Mar. 13 at 8:49 PM

$TRIB 👀

0 · Reply

ajmore Mar. 13 at 5:27 PM

$TRIB Time to add! added

0 · Reply

Clydagh Mar. 13 at 9:15 AM

$TRIB I have put my money where my mouth is. I have backed up the truck and loaded her up. We are very close now ...

1 · Reply

mechaniker06 Mar. 12 at 7:50 AM

$TRIB are they going to shit or get off the pot with their CGM or not, what is taking so damn long? if the EU approved it start contracting it out to make, get FDA and somebody like J&J have the ability to make it for the US market, everybody makes money

0 · Reply

MikiTrader Mar. 12 at 5:00 AM

$TRIB There is nothing wrong with what management announced. But think about why the stock didn't move up. And stop testing the market too much. Just deliver the results. Market expectations are high, so anything below the threshold will likely backfire.

0 · Reply

JackLalayne1 Mar. 11 at 9:19 PM

$TRIB

0 · Reply

Clydagh Mar. 11 at 1:49 PM

$TRIB Oh so now we are off to a big diabetics conf in Barcelone to a̶n̶n̶o̶u̶n̶c̶e̶ ̶C̶G̶M̶ ̶P̶a̶r̶t̶n̶e̶r̶s̶h̶i̶p̶ advance CGM collaborations

2 · Reply

Clydagh Mar. 11 at 11:55 AM

$TRIB Why “randomly” pre-announce Q4? 1) Get the bad news out of the way so it does not spoil the coming big news. 2) TRIB cannot execute Yorkville draws or debt conversions without up-to-date financial disclosure. But Yorkville and Perceptive cannot realistically happen without a share price closer to $5 So it seems something big and very good is about to be announced. I say it’s a CGM partnership. The CGM PR is preparing the ground for a bigger CGM announcement. The most interesting bit is “now advancing the CGM+ program through the final design phase and anticipates initiating a pivotal clinical trial in 2026, targeting regulatory submissions in key global markets immediately thereafter.” You don’t go after key global markets on your own. So expect the long awaited partnership with cash upfront and milestone payments -> Shares are completely repriced to $3-$10 range -> Perceptive swaps some debt for equity boosting them further -> TRIB draws some Yorkville cash.

1 · Reply

deepthinker Mar. 10 at 9:24 PM

$TRIB Here’s the thing about this CGM. It’s a real thing. It existed as a Waveform product and got CE mark in 2019, but it wasnt ready for prime time. Work was done on it between 2019 and 2024, when Perceptive passed it to Trinity. Trinity has worked on it for 2+ years, and we don’t know if they’ve been able to overcome its issues. Market doesn’t think it has.

1 · Reply

kd1313 Mar. 10 at 5:41 PM

$TRIB haha 🤣 I hate being right about this one.

0 · Reply

deepthinker Mar. 10 at 4:48 PM

$TRIB I wish I could tell you that these guys had a viable commercial product, because that’s worth $250-$300 million, minimum. But, we just don’t know due to a history of pumping (sometimes necessary, but you can only go to that well so many times). If it is real, the market will figure it out eventually.

0 · Reply

Stock_Catcher Mar. 10 at 11:45 AM

$TRIB Trinity Biotech Provides Business and Trading Update

0 · Reply

Think_Bigly Mar. 7 at 9:08 PM

$TRIB should sell IMMCO and partner CGM.

0 · Reply

Highflying Mar. 6 at 12:15 PM

$TRIB Abbott Safety Alert: Approximately 3 million FreeStyle Libre 3 and 3 Plus sensors were identified with a production issue causing falsely low readings, linked to 736 severe adverse events and seven deaths. While Abbott states the issue is corrected, the FDA advises against using affected sensors.

0 · Reply

brj1323 Mar. 5 at 4:35 PM

$TRIB added a few here she likes that $.70 support

0 · Reply

Market Cap	2.29M
Revenue (ttm)	61.56M
Net Income (ttm)	-31.79M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-51.64%
Debt to Equity Ratio	-1.62

Volume	106,000
Avg Vol	259,236
Day's Range	N/A - N/A
Shares Out	3.59M
Stochastic %K	3%
Beta	N/A
Analysts	Strong Buy
Price Target	$15.00